TerminatedPhase 3Results postedNCT03786094
Pivotal Study in HER2 Negative, Locally Recurrent or Metastatic Breast Cancer
Spexis AGn = 43230 May 2019 to 19 Oct 2021
Metastatic Breast Cancer · Locally Recurrent Breast Cancer
Balixafortide / Studies
Synthetic analog · 16 amino acids · 1,864.1 Da
Balixafortide studies and research data
PepBank has 5 balixafortide studies with results. 4 of them gave balixafortide, with 20 results, grouped by what the studies measured. In each group, results from studies in people come first. Data as of 2026-10-30.
Searches 20 results and 19 papers. Newer studies from Europe PMC
Results in people
9
45% of 20 results
Results in animals
10
50% of 20 results
Results in lab cells
1
5% of 20 results
From computer models
0
0% of 20 results
The molecule
Balixafortide identity
Identifiers, parent molecule, targets and development stage, from curated data.
Balixafortide is a 16-residue cyclic peptide, also called POL6326. It includes a diaminobutyric acid residue and D-proline substitutions. It differs from motixafortide and CXCR4-targeted imaging conjugates.
- Kind
- Synthetic analog · 16 residues
- Identifiers
- ChEMBLCHEMBL4802129 (opens in a new tab)PubChem CID138752609 (opens in a new tab)UNIIPRC974M49B (opens in a new tab)CAS1051366-32-5KEGGD12128 (opens in a new tab)IUPHAR11587 (opens in a new tab)
- Development
- Phase 3Polyphor / SpexisPhase 3 is the highest registered stage. FORTRESS stopped after failure to meet its primary endpoint. NCT06981806 lists a phase 1 pancreatic-cancer combination study as not yet recruiting. These records do not establish benefit or current program funding. Source (opens in a new tab)
Targets
| Target | Action | Evidence |
|---|---|---|
| CXCR4CXCR4P61073 (opens in a new tab) | Antagonist | IUPHAR identifies CXCR4 antagonism. UniProt identifies human CXCR4 as P61073.Source (opens in a new tab) |
Sequence and structure
Residues, differences from the parent, calculated properties and 3D structure. Source values and calculated values are shown separately.
Sequence
16 amino acids · 5 modifications · 1 disulfide bond
Residues 1 to 10:
ACSARYCY
Residues 11 to 16:
QKPYH
Properties
From identity sources
- Formula
- C84H118N24O21S2
- Molecular weight
- 1,864.1 g/mol
- Monoisotopic mass
- 1,862.8345 Da
- PubChem CID 138752609(opens in a new tab)retrieved 2026-10-27
- fda PRC974M49B(opens in a new tab)retrieved 2026-10-27
- iuphar 11587(opens in a new tab)retrieved 2026-10-27
- ChEMBL CHEMBL4802129(opens in a new tab)retrieved 2026-10-27
- kegg D12128(opens in a new tab)retrieved 2026-10-27
Calculated from the sequence
Some values cannot be calculated. The sequence has a non-canonical residue (X). Residue tables cover only the 20 standard amino acids.
- Average mass
- Not calculated
- Monoisotopic mass
- Not calculated
- Isoelectric point (pI)
- Not calculated
- Net charge at pH 7.4
- Not calculated
- GRAVY (hydropathy)
- Not calculated
- Extinction coefficient, 280 nm (Cys reduced)
- 4,470 M⁻¹ cm⁻¹
- 5500 x Trp + 1490 x Tyr · Pace et al. 1995 (ExPASy ProtParam)
- No Trp: ExPASy reports more than 10 % error without Trp.
- Extinction coefficient, 280 nm (all Cys as cystines)
- 4,595 M⁻¹ cm⁻¹
- 5500 x Trp + 1490 x Tyr + 125 x cystine · Pace et al. 1995 (ExPASy ProtParam)
- Instability index
- Not calculated
- Aliphatic index
- Not calculated
- Boman index
- Not calculated
- Hydrophobic moment (μH)
- Not calculated
- 1 non-canonical residue (X) is not included in calculated values.
- Not included: cyclization. Mass, charge and pI are not calculated; use the identity-source values.
- The N-terminal group is not modeled.
- The C-terminal group is not modeled.
- D-amino acids have the same mass and charge as L forms. Hydrophobicity scales were measured on L forms.
- Defined and validated for proteins; use with care for short peptides.
- Assumes an ideal alpha helix. Many short peptides are not helical.
@pepdb/chem 0.2.0 · EMBOSS pKa set · ExPASy residue masses
Net charge by pH
No charge curve
The sequence has a non-canonical residue (X). Residue tables cover only the 20 standard amino acids.
Composition
- Hydrophobic13% (2)A
- Aromatic19% (3)Y
- Positive19% (3)H K R
- Polar13% (2)Q S
- Special31% (5)C P
- Non-canonical6% (1)X
16 residues. Each residue counts in one class; F and W count as aromatic.
A Ala2 · 13%
I Ile0 · 0%
L Leu0 · 0%
M Met0 · 0%
V Val0 · 0%
F Phe0 · 0%
W Trp0 · 0%
Y Tyr3 · 19%
H His1 · 6%
K Lys1 · 6%
R Arg1 · 6%
D Asp0 · 0%
E Glu0 · 0%
N Asn0 · 0%
Q Gln1 · 6%
S Ser1 · 6%
T Thr0 · 0%
C Cys2 · 13%
G Gly0 · 0%
P Pro3 · 19%
X Xaa1 · 6%
3D structure
No 3D structure
No experimental structure (PDB) and no UniProt entry for an AlphaFold model are listed for this peptide. Synthetic peptides often have neither. The sequence view above is the reference.
Helical wheel
An ideal alpha-helix projection. It shows where the hydrophobic residues fall if the peptide folds as a helix. It does not show that it does.
- μH, residues shown
- 0.149
- μH, best 11-residue window
- —
- Arrow direction
- 71°
- Residues
- 16 · 1 X not scored
HydrophilicHydrophobic
Eisenberg consensus (normalized) scale · + K, R · − D, E
Assumes an ideal α-helix: 100° per residue, 3.6 residues per turn. The arrow is the mean hydrophobic moment (Eisenberg et al. 1984) and points at the hydrophobic face.
Show as table
| Position | Residue | Angle | Eisenberg consensus (normalized) |
|---|---|---|---|
| 1 | A | 0° | 0.62 |
| 2 | C | 100° | 0.29 |
| 3 | S | 200° | -0.18 |
| 4 | A | 300° | 0.62 |
| 5 | P | 40° | 0.12 |
| 6 | X | 140° | not scored |
| 7 | R | 240° | -2.53 |
| 8 | Y | 340° | 0.26 |
| 9 | C | 80° | 0.29 |
| 10 | Y | 180° | 0.26 |
| 11 | Q | 280° | -0.85 |
| 12 | K | 20° | -1.50 |
| 13 | P | 120° | 0.12 |
| 14 | P | 220° | 0.12 |
| 15 | Y | 320° | 0.26 |
| 16 | H | 60° | -0.40 |
Results by area
What the studies measured
People first in each area, then animals, then lab cells. Counts are exact and come from studies that gave the peptide.
Trials and papers
Newer studies
PepBank reads each paper before it shows the results. This search looks in Europe PMC for newer papers that PepBank has not read yet.
Status and safety
Data